| 2026-03-09 |
详情>>
内部人交易：
Ragosa Mark共交易6笔
|
| 2026-02-24 |
详情>>
股本变动：
变动后总股本7653.54万股
|
| 2026-02-24 |
详情>>
业绩披露：
2025年年报每股收益0.80美元,归母净利润5900.50万美元,同比去年增长236.61%
|
| 2026-02-24 |
财报披露：
美东时间 2026-02-24 盘前发布财报
|
| 2025-10-28 |
详情>>
业绩披露：
2025年三季报(累计)每股收益0.61美元,归母净利润4480.60万美元,同比去年增长230.61%
|
| 2025-07-29 |
详情>>
业绩披露：
2025年中报每股收益0.36美元,归母净利润2637.10万美元,同比去年增长222.02%
|
| 2025-04-29 |
详情>>
业绩披露：
2025年一季报每股收益0.12美元,归母净利润853.90万美元,同比去年增长148.23%
|
| 2025-04-21 |
股东大会：
将于2025-06-03召开股东大会
会议内容 ▼▲
- 1.To re-elect Sanj K. Patel, Thomas R. Malley and Richard S. Levy as Class I Directors to serve on the Board of Directors until the 2028 Annual Meeting of Shareholders, and until their respective successors have been appointed or until their earlier resignation or vacation of office in accordance with the Articles of Association (the “Articles”) of Kiniksa Pharmaceuticals International, plc (the “Company”).
2.To re-elect Stephen R. Biggar, G. Bradley Cole and Barry D. Quart as Class II Directors to serve on the Board of Directors until the 2026 Annual Meeting of Shareholders, and until their respective successors have been appointed or until their earlier resignation or vacation of office in accordance with the Articles.
3.To re-elect Felix J. Baker, Ph.D., M. Cantey Boyd, Tracey L. McCain and Kimberly J. Popovits as Class III Directors to serve on the Board of Directors until the 2027 Annual Meeting of Shareholders, and until their respective successors have been appointed or until their earlier resignation or vacation of office in accordance with the Articles.
4.To approve the appointment of PricewaterhouseCoopers LLP (“PwC”) as the Company’s UK statutory auditors until the close of our next Annual Meeting of Shareholders.
5.To ratify the appointment of PwC as the Company’s US independent registered public accounting firm for the fiscal year ending December 31, 2025.
6.To authorize the Board of Directors, through our Audit Committee, to determine PwC’s remuneration in its capacity as our UK statutory auditors until the close of our next Annual Meeting of Shareholders.
7.To receive the Company’s UK statutory annual accounts and report for the period ended December 31, 2024 (the “UK Annual Report”).
8.To approve, on an advisory (non-binding) basis, the Company’s UK Statutory Directors’ Annual Remuneration Report for the period ended December 31, 2024 (the “UK Remuneration Report”), which is set forth in Annex A to this proxy statement and contained in the UK Annual Report.
9.To approve the Company’s UK Statutory Directors’ Remuneration Policy (the “UK Remuneration Policy”), which is set forth in Annex A to this proxy statement and contained in the UK Annual Report.
10.To approve, on an advisory (non-binding) basis, the compensation of our named executive officers.
11.To authorize the Board of Directors, generally and unconditionally for the purpose of section 551 of the UK Companies Act 2006 (the “Companies Act”) to allot shares in the Company or to grant rights to subscribe for or to convert any security into shares in the Company (“Rights”) up to a maximum aggregate nominal amount of $6,976.33, which represents approximately 35% of the issued ordinary share capital of the Company on the Record Date. This authority shall expire (unless previously renewed, varied or revoked) on June 2, 2030, but we may at any time before the expiration of this authority make an offer or agreement which would or might require shares to be allotted, or Rights to be granted, pursuant to this authority after its expiration, and the Board of Directors may allot shares or grant Rights in pursuance of that offer or agreement as if the authority conferred by this resolution had not expired. The authority granted by this resolution shall replace all of our existing authorities to allot any shares and to grant Rights previously granted in connection with the adoption of the Articles in June 2024, but without prejudice to any allotment of shares or grant of Rights already made or agreed or offered to be made pursuant to such authorities.
|
| 2025-02-25 |
详情>>
业绩披露：
2024年年报每股收益-0.6美元,归母净利润-4319.3万美元,同比去年增长-406.68%
|
| 2025-02-25 |
详情>>
业绩披露：
2022年年报每股收益2.64美元,归母净利润1.83亿美元,同比去年增长216.11%
|
| 2024-10-29 |
复牌提示：
2024-10-29 09:33:41 停牌，复牌日期 2024-10-29 09:38:41
|
| 2024-10-29 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-0.16美元,归母净利润-1115.3万美元,同比去年增长-106.23%
|
| 2024-10-29 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-0.48美元,归母净利润-3430.5万美元,同比去年增长-207.59%
|
| 2024-07-25 |
详情>>
业绩披露：
2024年中报每股收益-0.31美元,归母净利润-2161.2万美元,同比去年增长-899.85%
|
| 2024-04-25 |
详情>>
业绩披露：
2024年一季报每股收益-0.25美元,归母净利润-1770.4万美元,同比去年增长-44.29%
|
| 2024-04-23 |
股东大会：
将于2024-06-05召开股东大会
会议内容 ▼▲
- 1.To elect Felix J. Baker, Ph.D., Tracey L. McCain and Kimberly J. Popovits as Class III Directors to serve on the Board of Directors until the 2027 Annual Meeting of Shareholders, and until their respective successors have been duly elected and qualified.
2.To approve the appointment of PricewaterhouseCoopers LLP (“PwC”) as our auditor until the close of our next Annual Meeting of Shareholders, to delegate to our Board of Directors, through our Audit Committee, the authority to set the auditor’s remuneration for such period, and to ratify the appointment of PwC as our independent registered public accounting firm for the fiscal year ending December 31, 2024.
3.To approve, on an advisory (non-binding) basis, the compensation of our named executive officers.
4.To transact such other business as may properly come before the Annual Meeting or any continuation, postponement, or adjournment of the Annual Meeting.
|
| 2024-02-28 |
详情>>
业绩披露：
2023年年报每股收益0.20美元,归母净利润1408.40万美元,同比去年增长-92.32%
|
| 2023-04-27 |
股东大会：
将于2023-06-06召开股东大会
会议内容 ▼▲
- 1.To elect Stephen R. Biggar, G. Bradley Cole and Barry D. Quart as Class II Directors to serve until the 2026 Annual Meeting of Shareholders, and until their respective successors have been duly elected and qualified.
2.To approve the appointment of PricewaterhouseCoopers LLP (“PwC”) as our auditor until the close of our next Annual Meeting of Shareholders, to delegate to our Board of Directors, through our Audit Committee, the authority to set the auditor’s remuneration for such period, and to ratify the appointment of PwC as our independent registered public accounting firm for the fiscal year ending December 31, 2023.
3.To approve, on an advisory (non-binding) basis, the compensation of our named executive officers.
4.To transact such other business as may properly come before the Annual Meeting or any continuation, postponement, or adjournment of the Annual Meeting.
|
| 2022-04-28 |
股东大会：
将于2022-06-29召开股东大会
会议内容 ▼▲
- 1.To elect Sanj K. Patel, Thomas R. Malley and Richard S. Levy as Class I Directors to serve until the 2025 Annual Meeting of Shareholders, and until their respective successors have been duly elected and qualified.
2.To approve the appointment of PricewaterhouseCoopers LLP (“PwC”) as our auditor until the close of our next Annual Meeting of Shareholders, to delegate to our Board of Directors, through our Audit Committee, the authority to set the auditor’s remuneration for such period, and to ratify the appointment of PwC as our independent registered public accounting firm for the fiscal year ending December 31, 2022.
3.To approve, on an advisory (non-binding) basis, the compensation of our named executive officers.
4.To transact such other business as may properly come before the Annual Meeting or any continuation, postponement, or adjournment of the Annual Meeting.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-28 |
股东大会：
将于2021-06-29召开股东大会
会议内容 ▼▲
- 1.To elect Felix J. Baker, Tracey L. McCain and Kimberly J. Popovits as Class III Directors to serve until the 2024 Annual Meeting of Shareholders, and until their respective successors have been duly elected and qualified.
2.To approve the appointment of PricewaterhouseCoopers LLP (“PwC”) as our auditor until the close of our next Annual Meeting of Shareholders, to delegate to our Board of Directors, through our Audit Committee, the authority to set the auditor’s remuneration for such period, and to ratify the appointment of PwC as our independent registered public accounting firm for the fiscal year ending December 31, 2021.
3.To approve, on an advisory (non-binding) basis, the compensation of our named executive officers.
4.To approve, on an advisory (non-binding) basis, the frequency of future advisory votes on the compensation of our named executive officers.
5.To transact such other business as may properly come before the Annual Meeting or any continuation, postponement, or adjournment of the Annual Meeting.
|
| 2020-04-28 |
股东大会：
将于2020-06-30召开股东大会
会议内容 ▼▲
- 1.To elect Stephen R. Biggar and Barry D. Quart as Class II Directors to serve until the 2023 Annual Meeting of Shareholders, and until their respective successors have been duly elected and qualified;
2.To approve the appointment of PricewaterhouseCoopers LLP ("PwC") as our auditor until the close of our next Annual Meeting of Shareholders, to delegate to our Board of Directors, through our Audit Committee, the authority to set the auditor's remuneration for such period, and to ratify the appointment of PwC as our independent registered public accounting firm for the fiscal year ending December 31, 2020;
3.To transact such other business as may properly come before the Annual Meeting or any continuation, postponement, or adjournment of the Annual Meeting.
|
| 2019-04-17 |
股东大会：
将于2019-05-29召开股东大会
会议内容 ▼▲
- 1.To elect (a) Sanj K. Patel, Thomas R. Malley and Richard S. Levy as Class I Directors to serve until the 2022 Annual Meeting of Shareholders, and until their respective successors shall have been duly elected and qualified, (b) Stephen R. Biggar and Barry D. Quart as Class II Directors to serve until the 2020 Annual Meeting of Shareholders, and until their respective successors shall have been duly elected and qualified, and (c) Felix J. Baker, Tracey L. McCain and Kimberly J. Popovits as Class III Directors to serve until the 2021 Annual Meeting of Shareholders, and until their respective successors shall have been duly elected and qualified;
2.To approve the appointment of PricewaterhouseCoopers LLP as our auditor until the close of our next Annual Meeting of Shareholders, to delegate to our Board of Directors, through our Audit Committee, the authority to set the auditor's remuneration for such period, and to ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2019;
3.To transact such other business as may properly come before the Annual Meeting or any continuation, postponement, or adjournment of the Annual Meeting.
|